Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence
Nature Medicine, Volume 29, No. 11, Year 2023
Notification
URL copied to clipboard!
Description
Pre-exposure prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate and emtricitabine administered orally daily is effective in preventing human immunodeficiency virus (HIV) acquisition in both men and women with sufficient adherence; however, the adherence–efficacy relationship in cisgender women has not been well established. We calculated the adherence–efficacy curve for cisgender women by using HIV incidence and plasma TFV concentration data from three trials (FEM-PrEP, VOICE and Partners PrEP). We imputed TFV diphosphate (TFV-DP) concentrations, a measure of long-term adherence, from TFV quantification by using data from the HIV Prevention Trials Network 082 study, which measured both TFV-DP and TFV concentrations. Two, four and seven pills per week reduced HIV incidence by 59.3% (95% credible interval (CrI) 29.9–95.8%), 83.8% (95% CI 51.7–99.8%) and 95.9% (95% CI 72.6–100%), respectively. Our adherence–efficacy curve can be validated and updated by HIV prevention studies that directly measure TFV-DP concentrations. The curve suggests that high adherence confers high protection in cisgender women. However, the lower efficacy with partial adherence highlights the need for new PrEP products and interventions to increase adherence. © 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.
Authors & Co-Authors
Stansfield, Sarah E.
United States, Seattle
Fred Hutchinson Cancer Center
United Kingdom, London
Imperial College London
Donnell, Deborah J.
United States, Seattle
Fred Hutchinson Cancer Center
Boily, Marie Claude
United Kingdom, London
Imperial College London
United Kingdom, London
Medical Research Council
Mitchell, Kate M.
United Kingdom, London
Imperial College London
United Kingdom, London
Medical Research Council
Anderson, Peter L.
United States, Aurora
University of Colorado Anschutz Medical Campus
Delany-Moretlwe, Sinead
South Africa, Johannesburg
University of the Witwatersrand
Bekker, Linda Gail
South Africa, Cape Town
Desmond Tutu Health Foundation
Mgodi, Nyaradzo Mavis
Zimbabwe, Harare
University of Zimbabwe
Celum, Connie L.
United States, Seattle
University of Washington
Dimitrov, Dobromir T.
United States, Seattle
Fred Hutchinson Cancer Center
United Kingdom, London
Imperial College London
United States, Seattle
University of Washington
Statistics
Citations: 1
Authors: 10
Affiliations: 8
Identifiers
Doi:
10.1038/s41591-023-02564-5
ISSN:
10788956
Research Areas
Health System And Policy
Infectious Diseases
Study Design
Cohort Study
Participants Gender
Male
Female